Resection of intraocular squamous cell carcinoma

D H Char, J Brooks Crawford, E L Howes Jr, A J Weinstein

Abstract
A patient with recurrent squamous cell carcinoma of the conjunctiva was referred with 20/20 vision in an eye with obvious intraocular extension. A modified iridocyclochorioretinectomy was performed and the tumour was removed. Three and a half years later the patient’s vision was 20/30 and there is no recurrence. This is the first case in which an eye has been successfully salvaged with documented intraocular squamous cell carcinoma of the conjunctiva.

Squamous cell carcinoma of the conjunctiva usually remains superficial, localised, and can be cured at that stage with resection and adjunctive cryotherapy or radiation. Rarely does the tumour invade either into the orbit or the globe. Approximately 60 cases of intraocular invasion have been reported. Usually this complication occurs in patients with either neglected or recurrent tumours. In a 60 year retrospective review from the Mayo Clinic there were two of 22 cases of invasive squamous cell carcinoma of the conjunctiva invaded into the globe. In a series of 104 epithelial tumours reported by Irvine, one had intraocular invasion; similarly one of 27 invasive carcinomas reported from the Wilmer Institute had intraocular penetration.

Intraocular invasion from squamous cell carcinoma of the conjunctiva can have a number of clinical manifestations. We have noted it as an undiagnosed corneal perforation, anterior segment inflammation, a combined orbital and intraocular mass, a non-specific broad peripheral anterior synchiae, an apparently solitary intraocular mass, or a sheet of cells growing onto the iris surface, or other presentations have included a necrotising scleritis. Nicholson and Herschler described a patient who presented with apparent anterior chamber inflammation in whom the correct diagnosis of squamous cell carcinoma was confirmed with aqueous paracentesis.

The ocular prognosis for patients with intraocular invasion from conjunctival carcinoma has been dismal. All reported cases have required either enucleation or exenteration. We report a patient with recurrent squamous cell carcinoma that invaded the globe in whom we were able to successfully salvage both the eye and vision.

Case report
A 58-year-old female was referred with a recurrent right conjunctival squamous cell carcinoma with intraocular invasion. The patient was initially examined in January 1987 by her local ophthalmologist for an atypical area of solar damage at the right temporal limbus. In February 1987 this was resected and pathological examination revealed a squamous cell carcinoma. The tumour recurred 6 weeks later and a second resection was performed in April 1987. An en bloc excision of the tumour and the underlying 50% thickness sclera was performed. Adjunctive cryotherapy was delivered to the remaining scleral fibres and the edges of the resection. The area was closed primarily without a graft. The neoplasm recurred within 1 month in the same area and a third resection was performed in May 1987 with placement of a 10 mm diameter scleral allogeneic patch graft. Pathology sections demonstrated that all margins were clear.

Two months later in July 1987 intraocular invasion was noted (Fig 1) and the patient was referred to us for further management.

On examination at that time the visual acuity was 20/20 in each eye. The left anterior segment and fundus were unremarkable except for areas of lattice degeneration without retinal breaks. The intraocular pressure was 14 mm Hg in the right eye and 16 mm Hg in the left.

In the right eye there was a large scleral graft at the temporal limbus. The cornea was clear. The iris and ciliary body were involved with an amelanotic mass from 7 to 9 o’clock. There was no pupillary distortion. There was trace flare without cell in the anterior chamber. Examination of the right fundus with both scleral depression and three mirror contact lens examination was unremarkable.

Ultrasonography demonstrated a mass involving the lens and ciliary body. The tumour was approximately 7 mm thick on standardised A scan.

Various therapeutic options were discussed with the patient and her family and it was decided to proceed with a scleral resection and a modified iridocyclectomy. The area around the scleral graft was explored and obvious tumour extension along both surface and under the graft.
allogenec scleral graft was used to reconstruct the eye. Double freeze thaw adjunctive cryo-
therapy to adjacent sclera and conjunctiva was
delivered in a standard manner. Microscopic
examination of the resected tissue showed a
keratinising squamous cell carcinoma arising
from the conjunctiva and extending through
canal into the ciliary body (Figs 2 A, B, C).
Postoperatively the patient slowly developed
increasing lens opacity over the next year. She
subsequently had an extracapsular cataract
elevation and the implantation of an intraocular
lens by her referring ophthalmologist in August
1989. A YAG laser capsulotomy was performed
and on her last visit in August 1990 her visual
acuity was 20/30. There was no evidence of
tumour recurrence and the pressure was 

Discussion
There are at least three important risk factors
for intraocular extension of squamous cell
carcinoma of the conjunctiva, neglected
malignancy, recurrent tumours, and histologic
tumour type.13 Our case had repeat excisions
with apparently clear margins but eventually
developed intraocular penetration. The disparity
between the apparently clear surgical margins
and recurrence emphasises the limitations of
standard frozen section control of tumour mar-
gins. While that histological technique is quite
accurate to delineate horizontal tumour spread,
especially with a small surgical specimen, its
efficacy for sampling the deep surface is poor.
We have had one other conjunctival tumour
patient with clear frozen section margins who
developed a recurrence because of inapparent
tumour at the deep surgical line. These limita-
Resection of intraocular squamous cell carcinoma

With frozen section technique have led us to use adjunctive cryotherapy both to the base as well as the horizontal resection lines in all cases.1

Intraocular penetration and metastases from squamous cell carcinomas of the conjunctiva are rare.2,3 16 In most series fewer then 2% of cases have intraocular penetration, and only two patients in the United States have had documented metastatic disease. In 10 patients reported from Saudi Arabia with advanced disease seven had intraocular invasion.17 Mucoid epidermoid and, possibly, spindle cell variants of squamous cell carcinoma are more locally aggressive and have a higher recurrence rate; each histological subtype account for fewer than 5% of squamous cell carcinomas of the conjunctiva.9 10 21

Very few surgeons have attempted to salvage an eye with intraocular penetration of squamous cell carcinoma of the conjunctiva; all previous cases have required either enucleation or exenteration.20 and co-workers reported two patients who had modified en bloc resections; however both had positive margins and were enucleated within 1 day and 1 week of the initial surgery.16 It is uncertain how many patients with intraocular proliferation of squamous cell carcinoma are candidates for a modified iridocyclochoroidectomy. We have examined five patients with intraocular extension from this tumour, and this was the only case in which we felt that this approach was indicated. Usually intraocular penetration by this malignancy is not amenable to local resection with ocular salvage because the tumour is too diffuse. Since 1903 a number of investigators have demonstrated that intraocular invasion is usually associated with diffuse spread in both the suprachoroidal space and the uvea.16 Often the tumour is sufficiently friable to seed cells into the anterior chamber and simulate inflammation.19 In some cases there is extensive orbital spread contiguous with the ocular involvement. In a minority of patients with apparently localised intraocular tumour a modified eyelid resection is a reasonable alternative.

This work was supported in part by NIH grant EYO 7504, and by unrestricted grants from That Man May See and Research to Prevent Blindness.